Sign in

Iain Bressendorff, MD PhD

@ibressendorff.bsky.social
885 followers 349 following 130 posts

Nephrologist, clinical trials, PRIMETIME study. CKD-MBD, GN, DKD, amateur 80’s musician, MTG #NephSky

PostsRepliesMedia
Reposted by Iain Bressendorff, MD PhD
Frank Harrell @f2harrell.bsky.social · 23/05/2026
TTE continues to have a net negative effect on research by providing window dressing for undesigned studies. Biggest deficiency: TTE does nothing for confounding and barely mentions it. fharrell.com/post/causal
fharrell.com
Causal by Design – Statistical Thinking
Well-controlled randomized experiments when analyzed in a randomization-respecting way are causal by design and need no causal calculus to infer causation. If an observational study has any hope of pr...
041
Reposted by Iain Bressendorff, MD PhD
Kidney International @kidneyint.bsky.social · 28/04/2026
A randomized controlled non-inferiority trial examined lower dose prednisolone and activated vitamin D in adult minimal change podocytopathy doi.org/10.1016/j.kint.2026.02.035 #NephSky #MedSky #OpenAccess #NephroticSyndrome
031
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 17/04/2026
& I will go one step further The A-C-D combo as first line is based on ALLHAT where Spiro was not on the table arguably Spiro could even be first line in primary hypertension if we did ALLHAT 2.0 Sodium (yes I am saying that) is so important that Spiro/HCTZ combo makes a great first line drug
152
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 05/04/2026
Since atrasentan is bound to be approved for use in IgAN, does anyone know whether it will be revived for DKD? SONAR did in fact show that it was effective, but the premature termination and upstaging by CREDENCE sort of left atrasentan for dead… #askrenal
120
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 28/03/2026
Interesting trial in @kidneyint@bsky.social www.kidney-international.org/article/S008... SLE with remission. No symptoms. When dsDNA becomes positive (or doubles) do you preemptively increase immunosuppression? #NephSky #RheumSky
Figure 2 Survival at 24-month from randomization free of (A) renal flares, (B) extra-renal flares and (C) overall clinical flares in lupus nephritis patients presenting with asymptomatic serological reactivation and randomized to receive pre-emptive treatment (PT Group) or observant management (Control Group).
164
Reposted by Iain Bressendorff, MD PhD
Anand Vaidya @anandvaidya17.bsky.social · 26/03/2026
"Over 80% of participants with obesity-related hypertension exhibited reproducible pathologic phenotypes of aldosteronism and/or hypercortisolism" www.jacc.org/doi/10.1016/...
jacc.org
Unmasking Hormonal Mechanisms of Hypertension in Obesity:
083
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 11/03/2026
Research letter, pilot trial from Mayo ($locked) pubmed.ncbi.nlm.nih.gov/41802270/ Diuretic resistance is mostly inadequate furosemide dose. Torsemide not needed™️ (Incidence of deafness 🧏🏽‍♂️ not reported)
Figure one showing more divers with high dose furosemide
1143
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 08/03/2026
Is anyone using obinutuzumab for maintenance in SLE (I know there is no data)? Have young pt with LN III/IV, MMF + prednisone induction. Doing well, but persistently high dsDNA, C3/C4 normal. @kidneydoc101.bsky.social @juancarlosqvelez.bsky.social @kronbichlerlab.bsky.social @grahamabra.bsky.social
254
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/03/2026
We report it for outpatients We don’t report it for inpatients - it’s easy to calculate if you want to
131
Reposted by Iain Bressendorff, MD PhD
PEnghard @penghard.bsky.social · 28/02/2026
Very cool paper from Hamburg! Urinary CD4+ T cells identify Sjögren's patients with nephritis and help monitor treatment response! Awesome work! pubmed.ncbi.nlm.nih.gov/41673408/ #NephSky
033
Reposted by Iain Bressendorff, MD PhD
Jeff Miner @jeffminerphd.bsky.social · 26/02/2026
Glomerular basement membrane (GBM) structural integrity dictates trans-tissu... www.sciencedirect.com/science/arti... Really proud of this Cell Reports paper showing that the potentially pathogenic laminin alpha2 in the Alport GBM comes not from glomerular cells, but from the bloodstream.
sciencedirect.com
Glomerular basement membrane structural integrity dictates trans-tissue deposition of laminin in the kidney
Basement membranes (BMs) are specialized extracellular matrices (ECMs) essential for tissue structure and function. In non-vertebrates, ECM components…
1109
Reposted by Iain Bressendorff, MD PhD
Joel Topf @kidneyboy.bsky.social · 25/02/2026
The things that have changed or most influenced my approach to anemia are: Daniel Coyne DRIVE 2 PIVOTAL CHOIR/CREATE/TREAT (No KDOQI or KDIGO guideline) #NephJC
184
Reposted by Iain Bressendorff, MD PhD
Cristina Popa @nephroseeker.medsky.social · 25/02/2026
Or seeing a lot of young patients with positive cross-matches and with no other cause of allo-/isoimmunization. If not the principal cause of their symptoms/ death-treatening, I always think twice if it's worth it #nephjc
151
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 13/02/2026
fun review if anyone is interested www.ahajournals.org/doi/10.1161/... Vaughan Pendred was a house surgeon at Guy's hospital when he reported deaf-mutism with goitre www.sciencedirect.com/science/arti... in @thelancet.com - and went on to become a ....(not nephrologist) a general practitioner
ahajournals.org
Regulation of Blood Pressure and Salt Balance By Pendrin-Positive Intercalated Cells: Donald Seldin Lecture 2020 | Hypertension
Intercalated cells make up about a third of all cells within the connecting tubule and the collecting duct and are subclassified as type A, type B and non-A, non-B based on the subcellular distributio...
085
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 20/02/2026
@dialysisbloke.bsky.social Applied the VIPAR protocol to a patient with cAMR, first time in our centre. Fingers crossed for positive results 🤞🏻 Just wanted to let you know that it’s being used out there 🤓
131
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 20/02/2026
Another trial! Albumin 20% for septic shock Does not work - JAMA NO jamanetwork.com/journals/jam... #EMIMCC
Visual abstract
1195
Reposted by Iain Bressendorff, MD PhD
American Statistical Association History of Statistics @hos-asa.bsky.social · 03/01/2026
#OTD 1917 David Finney b (d 12 Nov 2018) CBE FRS; ASA Fellow 1951; Royal Statistical Society President 1973. Pioneered statistical methods of experimental design, statistical computing, pharmacovigilance, biological assay & probit analysis. 1/3
142
Reposted by Iain Bressendorff, MD PhD
Steffen Flindt Nielsen @nicenielsen.bsky.social · 16/12/2025
Still interested in the mechanisms of #SGLT2i? I did a video with #Vumedi going through our study on the effects of empagliflozin on fluid and electrolyte balance. check it out: www.vumedi.com/video/fluid-... Link for the studies 👇 #medsky #nephsky
vumedi.com
Fluid Balance in CKD: Empagliflozin Findings from SiRENA
A video from William Shaffer (as part of ASN Kidney Week Highlights), posted on Nov 26, 2025.
111
Reposted by Iain Bressendorff, MD PhD
Juan Carlos Q Vélez, MD @juancarlosqvelez.bsky.social · 16/12/2025
Important study validating what has become my standard practice for relapsing MCD-NS
161
Reposted by Iain Bressendorff, MD PhD
Joel Topf @kidneyboy.bsky.social · 28/11/2025
Join the Filtrate and Jon Barratt as he takes an IgAN inspired victory lap FF 86 Atacicept for IgAN www.nephjc.com/freelyfilter...
nephjc.com
FF 86 Atacicept for IgAN with Jon Barratt — NephJC
FF 86 Atacicept for IgAN with Jon Barratt
2185
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 23/11/2025
I’m a little shocked at this review of resistant hypertension in CKD. academic.oup.com/ckj/advance-... - Weird take on BP targets (there are other trials besides SPRINT) - Thiazides don’t work in CKD, except chlorthalidone (demonstrably false) - Don’t use spiro if eGFR <45 because hyperK ?!?!? 1/2
academic.oup.com
2025 Update on resistant hypertension in CKD: where do we stand and where do we go?
Abstract. Resistant hypertension is highly prevalent among individuals with chronic kidney disease (CKD) and is closely associated with accelerated decline
282
Reposted by Iain Bressendorff, MD PhD
Juan Carlos Q Vélez, MD @juancarlosqvelez.bsky.social · 21/11/2025
7. Personal level. Beyond his talent and expertise, I met an extraordinary man. Humble, altruistic, wise, friendly, and with a great sense of humor. I brought him a vacuolar cast tie as a present and he wore it proudly right away 🤩
1143
Reposted by Iain Bressendorff, MD PhD
Juan Carlos Q Vélez, MD @juancarlosqvelez.bsky.social · 21/11/2025
1/n Recently attended an international congress about Urinalysis in Santiago, Chile 🇨🇱. I was expecting a small meeting. I was wrong. Pleasantly surprised with the size of the meeting and the energy and interest from the participants. Let me share the highlights of my experience:
2177
Reposted by Iain Bressendorff, MD PhD
Jonathan Zuckerman MD PhD @jzrenalpath.bsky.social · 20/11/2025
Diagnosis unmasked. Young F with 2g proteinuria, weak +dsDNA. Membranous pattern, IF with C3 dominant staining. Pronase IF --> IgG-k. Membranous-like glomerulopathy with masked monotypic IgG-k deposits. Considered to be autoimmune; not MGRS. #renalpath #pathsky #nephsky.
397
Reposted by Iain Bressendorff, MD PhD
Steffen Flindt Nielsen @nicenielsen.bsky.social · 09/11/2025
Nothing works in dialysis - except fis oil. Truly amazing data from the PISCES. Should we begin perscribimg fish oil supplements to all our dialysis patients? In spite of my somewhat sceptical priors, I think the answer should be “yes” #NephSky #KidneyWk #nephrology
193
Reposted by Iain Bressendorff, MD PhD
gearoidmm @gearoidmm.bsky.social · 04/11/2025
Not all heroes wear capes. xkcd.com/3163/
xkcd.com
Repair Video
011
Reposted by Iain Bressendorff, MD PhD
Lennard Ostendorf @lostendorf.bsky.social · 05/11/2025
What mechanisms drive checkpoint inhibitor-associated interstitial nephritis (ICI-AIN)? In our preprint, we identify CD8 T cells as a central player, inducing a proinflammatory myeloid cell state by IFNg and structuring lymphoid aggregates by CXCL13. www.biorxiv.org/content/10.1... 1/n #Nephsky 🧪
CD8 T cells produce IFNg and CXCL13 in TLS
164
Reposted by Iain Bressendorff, MD PhD
Joel Topf @kidneyboy.bsky.social · 05/11/2025
After a 40 minute handa on session where my station worked on kidney US we are back in the lecture room for a talk on lung ultrasound by Nathaniel Reisinger #KidneyWk
173
Reposted by Iain Bressendorff, MD PhD
Bo Abrahamsen @drboabrahamsen.physician.dk · 02/11/2025
I enjoyed the Observer this morning @drjennings.bsky.social In my considered view politicians and public bodies should not be on Twitter is for the same reason that a candidate should not attend a townhall meeting where he was put on a lower chair and very loud music played whenever he spoke.
011
Reposted by Iain Bressendorff, MD PhD
Juan Carlos Q Vélez, MD @juancarlosqvelez.bsky.social · 23/10/2025
Clinic visit, pt w/type 2 diabetes + nephrotic range proteinuria. Persistent hematuria noted (normal cysto 3 mo ago) not c/w diabetic nephropathy. #UrinarySediment 🔬is performed: numerous acanthocytes and a few WBC casts. Serum IgA elevated. Normal C3/C4. Other tests pending. Kidney biopsy planned
1185
Reposted by Iain Bressendorff, MD PhD
Joel Topf @kidneyboy.bsky.social · 21/10/2025
New episode of Freely Filtered with @brendonneuen.bsky.social @hswapnil.medsky.social @captainchloride.bsky.social @sophia-kidney.bsky.social and author Muth Vaduganathan discussing the CONVINCE trial www.nephjc.com/freelyfilter... With chapters, refs, and pictures
075
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 27/09/2025
A little opinion piece on the relationship between serum calcification propensity (T50) and progressive CAC in kidney transplant recipients 🤓 www.kireports.org/article/S246...
kireports.org
T50 and Calcification Progression in Kidney Transplant Recipients: Does it have to be “bad” to be useful?
The increased risk of cardiovascular disease (CVD) among kidney transplant recipients (KTR)1 is challenging for the treating physician. For KTR, CVD risk remains higher than for individuals with simil...
021
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 26/09/2025
And it’s live Iptacopan in C3GN makes it to @thelancet.com www.thelancet.com/journals/lan... #NephSky
thelancet.com
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study
Iptacopan showed a statistically significant, clinically meaningful proteinuria reduction in addition to RAAS inhibitors and immunosuppression at 6 months. Iptacopan was well tolerated with an accepta...
12311
Reposted by Iain Bressendorff, MD PhD
Jonathan Zuckerman MD PhD @jzrenalpath.bsky.social · 06/08/2025
Wide variety of morphologies in this case of crystalline light chain proximal tubulopathy: mottle lysosomes, crystals, and fibrils. #renalpath #nephsky #pathsky
096
Reposted by Iain Bressendorff, MD PhD
grahamabra.bsky.social @grahamabra.bsky.social · 13/09/2025
Have hyperglycemia (and other DM badness) been hiding in plain sight in ESKD? Probably. Great study using CGMs in ESKD. Pts with treated DM, mean TIR only 43% while mean HbA1c was 7.0% journals.lww.com/jasn/abstrac...
journals.lww.com
Glycemia Assessed by Continuous Glucose Monitoring among... : Journal of the American Society of Nephrology
ilure and its treatments disrupt glucose homeostasis in ways that may promote both hyperglycemia and hypoglycemia. Continuous glucose monitoring (CGM) delineates detailed glycemic profiles, but publis...
3127
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 23/08/2025
RIP Nicolas Madias Of the Adrogue-Madias formula and much more I don’t know he wrote three textbooks as a medical student! www.kidney-international.org/article/S008... In @kidneyint.bsky.social #NephSky
053
Reposted by Iain Bressendorff, MD PhD
Hans-Joachim Anders @hjanders.bsky.social · 12/08/2025
Now online in @ndt-era.bsky.social Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease 🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD ▶️ academic.oup.com/ndt/article-...
022
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 13/08/2025
Does anyone have experience with RTX for anti-GBM disease? Specifically, elderly/frail patients with anuria and no DAH. Kidneys lost, but high risk with CYC. Systematic review in KI Reports doesn’t entirely answer my Q @juancarlosqvelez.bsky.social @kronbichlerlab.bsky.social @lastwalsh.bsky.social
332
Reposted by Iain Bressendorff, MD PhD
Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 01/08/2025
Amazing! New species = new DNA to sequence = new knowledge = new breakthroughs at the horizon . Science won’t stop
011
Reposted by Iain Bressendorff, MD PhD
Joel Topf @kidneyboy.bsky.social · 26/07/2025
Isidore Edelman, father of the Edelman formula was a victim of McCarthyism. Lost his grant and federal funding after being accused of being Red. The American Heart Association stepped up to back fill his funding which allowed him to continue his work on salt and water
1339
Reposted by Iain Bressendorff, MD PhD
Marion Campbell @marionkcampbell.bsky.social · 21/07/2025
We often now hear the term “Bayesian borrowing” in trials. But what is Bayesian borrowing and what are the pros and cons around its use? 1/6 #MethodologyMonday #122
12011
Reposted by Iain Bressendorff, MD PhD
Brendon Neuen @brendonneuen.bsky.social · 15/07/2025
Reduction in all-cause hospitalisation driven by fewer admissions for: - Cardiac - Renal - Metabolic disorders, and - Infections Interestingly reduction in infections also observed with semaglutide in the FLOW trial - could GDMT improve physical resilience & susceptibility to infections?
021
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 15/07/2025
In resistant HTN guidelines say RAASi + CCB + thiazide followed by spiro. When BP at target, do you try discontinuing the first 3 and ramp up spiro? Or leave them on 4 drugs? (obviously first rule out primary hyperaldo) @hswapnil.medsky.social @drjmluther.bsky.social @jordybc.bsky.social
331
Reposted by Iain Bressendorff, MD PhD
Brendon Neuen @brendonneuen.bsky.social · 15/07/2025
SGLT2i in CKD: impact beyond kidneys 🔻 15% all-cause hospitalizations ✅ Consistent regardless of eGFR, UACR & diabetes 🏥 ~36 fewer hospitalizations per 1000 pt-years Large absolute gains for patients & health systems Meta-analysis in @asnpublications.bsky.social journals.lww.com/cjasn/pages/...
11310
Reposted by Iain Bressendorff, MD PhD
Marion Campbell @marionkcampbell.bsky.social · 07/07/2025
“Lasagna’s Law” describes the often observed phenomenon that as soon as you start your clinical trial the number of potentially eligible patients you expect to see/recruit suddenly appears to plummet. 2/7
386
Reposted by Iain Bressendorff, MD PhD
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 04/07/2025
RIP Alan Jardine journals.lww.com/jhypertensio...
The late Alan Jardine
0101
Reposted by Iain Bressendorff, MD PhD
Lucile Figueres @lucilefigueres.bsky.social · 07/06/2025
Proud to have contributed to our ERA Genes&Kidney working group consensus statement on CKDx (X for unexplained cause) published in #NDT. Transparent classification is of great benefits for patients and accelerates research ! academic.oup.com/ndt/advance-...
042
Reposted by Iain Bressendorff, MD PhD
Johann Morelle @johannmorelle.bsky.social · 29/04/2025
🔥 Final (pdf) version available online (free): Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy @ajkd.bsky.social ➡️ doi.org/10.1053/j.aj... #OpenAccess 🙏 to all collaborators and sponsors!
153
Reposted by Iain Bressendorff, MD PhD
Johann Morelle @johannmorelle.bsky.social · 31/03/2025
Grateful for the opportunity to work with such a team — to expand the original technique of laser capture microdissection and mass spectrometry for the identification of target antigens in membranous nephropathy ✨
052